Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,631 signal articles · 32 in last 24h · 155,698 total before filter · latest 1h ago
32last 24h
848last 7d
142● bullish (7d)
89● bearish (7d)
214publishers
AllMacro196Earnings106M&A122Regulatory20Product21Analyst19
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Can UNH Stock Keep Growing Earnings While Its Sales Stall?
Trefis4d agoneutral
Can UNH Stock Keep Growing Earnings While Its Sales Stall?

UnitedHealth (UNH) has turned its profits around. Operating earnings rose 55% in the second quarter of 2026, and management raised its full-year adjusted earnings guide to $19.50 to $20 a share. Revenue, though, has nearly stopped growing. So the rest of the recovery rests on something the company only partly controls: the medical bills of the people it insures.

ETF Zoo: 6 Pundits Walk Into a Bar
etf.com4d agoneutral
ETF Zoo: 6 Pundits Walk Into a Bar

<p>The <em>ETF Zoo</em> shakes things up in this special episode recorded on-stage from Future Proof. Don't miss as Dave Nadig puts James Seyffart, Cinthia Murphy, Ben Johnson, Todd Sohn, and Sumit Roy in the hot seat in this gameshow style paddle game of agree of disagree that covers a host of ETF-centric topics, and the debates that spark from some of the surprising answers. </p>

Cognex Acquires RealSense for $500M to Expand Robotic Vision Platform
MarketBeat4d agoneutral
Cognex Acquires RealSense for $500M to Expand Robotic Vision Platform

Cognex (NASDAQ:CGNX) said it has entered into a definitive agreement to acquire RealSense, a provider of depth-sensing cameras and vision technology used in robotic perception and physical AI applications. The transaction is intended to expand Cognex’s machine-vision portfolio into 3D depth percept

Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
Benzinga4d agoneutral
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug

Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program. The move is coming even as S&P 500 futures are up 0.1%, pointing to stock-specific pressure rather than a broad risk-off tape. Read Also: Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care CMPX Stock Drops After FDA Feedback On Tovecimig BLA Path Compass said the FDA recommended the company run a t

3 Big Tech Stocks With the Most Upside Right Now
24/7 Wall St.4d agoneutral
3 Big Tech Stocks With the Most Upside Right Now

Wall Street has targets for Google, NVIDIA, and Salesforce, but one analyst thinks those numbers still leave serious money on the table heading into 2027. Here is the math behind three bold calls that could reshape how you size your tech positions.

3 Reasons Investors Watch Skyward Specialty Insurance (SKWD)
StockStory4d agoneutral
3 Reasons Investors Watch Skyward Specialty Insurance (SKWD)

Skyward Specialty Insurance has had an impressive run over the past six months as its shares have beaten the S&P 500 by 17.7%. The stock now trades at $57.18, marking a 33.9% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

Apple doesn't need to be in first place for AI. Here's why.
Yahoo Finance Video4d agoneutralVIDEO
Apple doesn't need to be in first place for AI. Here's why.

Apple (AAPL) stock hit a record high on Tuesday, driven by the latest fanfare over its foldable iPhone Duo. Today's Market Hang panel consists of Host Turney Duff, Yahoo Finance Executive Editor Brian Sozzi, Defiance ETFs CIO Sylvia Jablonski, Interactive Brokers chief strategist Steve Sosnick, and Gerber Kawasaki Wealth & Investment Management CEO Ross Gerber.